Table 2.
Characteristic of the infection
| Variable | Cefiderocol group n = 27 |
BAT group n = 54 |
p value |
|---|---|---|---|
| Pathogen identified | |||
| Pseudomonas aeruginosa | 22 (81.5%) | 44 (81.5%) | |
| Acinetobacter baumannii | 4 (14.8%) | 8 (14.8%) | |
| Stenotrophomonas maltophilia | 1 (3.7%) | 2 (3.7%) | |
| Localization of the infection | 0.054 | ||
| Pneumonia | 21 (77.8%) | 51 (94.4%) | |
| Bloodstream infection | 6 (22.2%) | 3 (5.6%) | |
| Polymicrobial infection | 22 (81.5%) | 36 (66.7%) | 0.257 |
| Number of associated pathogen | 0.147 | ||
| 1 | 13 (59.1%) | 27 (75.0%) | |
| 2 | 5 (22.7%) | 8 (22.2%) | |
| ≥3 | 4 (18.2%) | 1 (2.8%) | |
| Antibiotic therapy | |||
| Cefiderocol | 27 (100%) | 0 (0%) | |
| Ceftazidime avibactam | 0 (0%) | 28 (51.9%) | |
| Ceftolozane/tazobactam | 0 (0.0%) | 8 (14.8%) | |
| Carbapenem | 0 (0.0%) | 2 (3.7%) | |
| Imipenem/cilastatin/relebactam | 0 (0.0%) | 2 (3.7%) | |
| Aztreonam | 0 (0.0%) | 2 (3.7%) | |
| Trimethoprim/sulfamethoxazole | 0 (0.0%) | 1 (1.9%) | |
| Fluoroquinolone | 0 (0.0%) | 6 (11.1%) | |
| Colistin | |||
| Intravenous | 1 (3.7%) | 14 (25.9%) | |
| Inhaled | 6 (22.2%) | 16 (29.6%) | |
| Duration of antimicrobial therapy | 13 [8–15] | 14 [12–15] | 0.241 |